Two versions of the same peptide. Completely different experiences.
If you have looked into growth hormone peptides, you have seen both names: CJC-1295 and CJC-1295 with DAC. They sound interchangeable. They are not. The DAC (Drug Affinity Complex) changes everything about how the peptide behaves in your body, how often you inject, and what kind of results you can expect.
Our dosage guide covers the clinical numbers. Our Ipamorelin + CJC-1295 stack guide explains the synergy. This article is about a different question: which version is right for you?
The Core Tradeoff: Convenience vs. Control
This is the decision in one sentence.
CJC-1295 with DAC stays active in your body for 6-8 days. You inject once or twice a week. Growth hormone stays elevated continuously.
CJC-1295 without DAC (also called Mod GRF 1-29) is active for about 30 minutes. You inject 2-3 times daily. Growth hormone rises in a short burst, then returns to baseline.
Convenience vs. control. That is the fundamental choice.
When the DAC Version Makes Sense
You want simplicity above everything else. One or two injections per week, no timing around meals or workouts, no carrying vials to the gym. If you travel frequently, work unpredictable hours, or simply want the lowest possible friction, DAC delivers.
You are focused on recovery and general wellness. The sustained GH elevation from DAC is well-suited for people who want the broad benefits of higher growth hormone (better sleep, improved skin, faster recovery from daily wear and tear) without optimizing for any single outcome.
You are not stacking with Ipamorelin or other GHRPs. DAC works fine on its own. Its long half-life means it is always providing a baseline GHRH signal. Adding a GHRP on top of continuous GHRH stimulation is possible but makes timing less intuitive.
The Catch
Continuous GH elevation is not how your body naturally works. Your pituitary releases growth hormone in pulses, with the biggest pulse during deep sleep. The DAC version bypasses this natural rhythm entirely.
In the original ConjuChem dose-escalation study (Ionescu & Bhatt, 2006), a single subcutaneous dose of CJC-1295 with DAC elevated GH levels for 6+ days. While this confirms DAC's extended activity, it also raised the question of whether sustained GHRH signaling could lead to pituitary desensitization over time. Human data on long-term continuous use remains limited.
There is also the "GH bleed" concern. Because DAC keeps GHRH signaling active around the clock, your pituitary never fully rests between pulses. In theory, this could reduce the amplitude of each individual GH pulse compared to the sharp, defined pulses you get without DAC.
When the No-DAC Version Makes Sense
You want to preserve your body's natural GH rhythm. Mod GRF 1-29 triggers a sharp pulse that looks almost identical to what your hypothalamus does naturally. Your pituitary fires, releases GH, and then goes quiet until the next injection. This pulsatile pattern is what most peptide clinics and experienced users prefer, and it aligns with the body's natural secretion rhythm described in endocrinology literature (Veldhuis et al., 1995).
You are stacking with Ipamorelin. This is the gold standard combination for a reason. Mod GRF 1-29 (the "go" signal) paired with Ipamorelin (the "volume knob") produces a stronger, cleaner GH pulse than either peptide alone. In a key selectivity study, Ipamorelin was shown to stimulate GH release without raising cortisol or prolactin (Raun et al., 1998), making it the cleanest GHRP to pair with a GHRH analog. The short half-lives match perfectly: inject both in the same syringe, get a defined pulse, done. Our stack guide goes deep on this.
You want to time GH release around specific events. Some users time their injections around workouts (post-training pulse for recovery) or before bed (amplify the natural sleep pulse). The short half-life of Mod GRF 1-29 gives you this precision. With DAC, timing is irrelevant because the peptide is always active.
You are more experienced with peptides. Multiple daily injections require more discipline, more reconstitution math, and more careful storage. This is not a beginner-friendly protocol.
The Catch
2-3 injections per day is a real commitment. Many people start with the best intentions and drift into inconsistency after a few weeks. An inconsistent no-DAC protocol will underperform a consistent DAC protocol every time. This is one of the most common observations in peptide community forums: compliance determines results more than the specific variant you choose.
What the Research Shows
The DAC version has the stronger published clinical data. The ConjuChem dose-escalation trial (Ionescu & Bhatt, 2006) demonstrated that single subcutaneous doses of 30-60 mcg/kg produced dose-dependent GH elevation lasting 6+ days, with IGF-1 increases of 1.5-3x above baseline sustained for 8-14 days.
A follow-up study confirmed that weekly dosing maintained elevated IGF-1 without significant safety signals over the study period (Teichman et al., 2006).
The no-DAC version (Mod GRF 1-29) has pharmacokinetic data confirming its rapid absorption and short activity window, building on the original GRF 1-29 (Sermorelin) research. However, fewer published human trials study long-term outcomes for the Mod GRF 1-29 + Ipamorelin combination specifically. Most of the evidence for this stack comes from clinical practice at peptide therapy clinics and consistent community reporting.
Neither version is FDA-approved for any indication.
A Decision Framework
Answer these three questions:
1. How many injections per day are you willing to do?
- 1-2 per week: DAC
- 2-3 per day: No-DAC
2. Are you stacking with Ipamorelin?
- Yes: No-DAC (the half-lives match, and pulsatile release is the whole point of the stack)
- No: Either works, but DAC is simpler
3. Do you care about mimicking natural GH patterns?
- Yes: No-DAC preserves pulsatile release
- No or unsure: DAC is fine
If you answered "DAC" to all three, go with DAC. If any answer pointed to no-DAC, start there. The no-DAC + Ipamorelin stack is the most validated approach in clinical practice, even if DAC has stronger published trial data.
One More Thing
Vendor labeling is inconsistent. Some vendors sell Mod GRF 1-29 labeled as "CJC-1295 no DAC." Others sell CJC-1295 with DAC labeled as just "CJC-1295." Always confirm which version you are looking at. If the dosing instructions say "inject daily" or "inject with Ipamorelin," it is the no-DAC version. If they say "inject weekly," it is DAC.
For reconstitution and exact dosing numbers, use our CJC-1295 dosage guide and the peptide dosage calculator.
References
- Ionescu M, Bhatt DL. "Pharmacokinetics and pharmacodynamics of CJC-1295, a long-acting growth hormone-releasing hormone analog." J Clin Endocrinol Metab. 2006. PubMed
- Teichman SL, et al. "Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults." J Clin Endocrinol Metab. 2006. PubMed
- Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998. PubMed
- Veldhuis JD, et al. "Physiological basis and pathophysiological significance of growth hormone secretory dynamics." Endocr Rev. 1995. PubMed
This article is for educational and informational purposes only. CJC-1295 is not FDA-approved for human use. Always consult a qualified healthcare provider before starting any peptide protocol.
